Common Mistakes & Audits

20
Common Mistakes & Audits 05/21/2014

description

Common Mistakes & Audits. Summary of audit findings by category. Common Mistakes. Delegating responsibility rather than authority The PI is always responsible for all study activity and for all personnel performance Lesson to be learned….PI - PowerPoint PPT Presentation

Transcript of Common Mistakes & Audits

Page 1: Common Mistakes  & Audits

Common Mistakes & Audits

05/21/2014

Page 2: Common Mistakes  & Audits

0 10 20 30 40 50

Discrepancies in Documentation of Informed Consent

Protocol Deviations

Personnel Changes Not Reflected in Study Documentation

Discrepancies in Reporting Adverse Events to IRB

Errors made by IRB

Lack of Required Training

Deviations from Good Clinical Practice

Disrepancies in Subject Data

Other

Summary of audit findings by category

Page 3: Common Mistakes  & Audits

Common Mistakes

• Delegating responsibility rather than authority

• The PI is always responsible for all study activity and for all personnel performance

Lesson to be learned….PIPick your sub-investigators and

coordinators carefully!

Page 4: Common Mistakes  & Audits

Common Mistakes

• Informed ConsentThis is the Achilles heel of research and

is the most commonly cited in litigation

Page 5: Common Mistakes  & Audits

Common Mistakes

• Not keeping the IRB informed of study changes and updates

Especially in sponsored research we have a sponsor that continually monitors study activity- it is a common mistake to notify the sponsor of problems and forget to notify the IRB

Page 6: Common Mistakes  & Audits

Common TTUHSC Audit Findings

• Discrepancies in executed Informed Consent Documents, such as:– Person signing as PI/Authorized Representative is

not authorized to sign– PI/Authorized Representative fails to date– PI/Authorized Representative signature date

different than Subject signature date– Most recent IRB-approved Informed Consent

Document not utilized (old form is used)

Page 7: Common Mistakes  & Audits

Common TTUHSC Audit Findings

Page 8: Common Mistakes  & Audits

Common TTUHSC Audit Findings

• Serious Adverse Events not reported to the IRB promptly (for example, SAE reporting to the IRB done months later at the request of the sponsor)

• No source documentation available to verify that the subjects received a copy of the Informed Consent Document

• Signed original Informed Consent Documents not consistently stored in the same location (for example, a majority of originals are found in the individual subject binders and a few originals are found in the medical record)

• Investigators and/or research staff lacking TTUHSC human research protection training and/or HIPAA for Researchers training

• Failure to submit amendments to the IRB regarding protocol modifications or changes in investigators and research staff

Page 9: Common Mistakes  & Audits

Common TTUHSC Audit Findings

• Subject reimbursement procedures.• Non-research staff involved in the research process.

Page 10: Common Mistakes  & Audits

Sponsor Audits

• Purpose: to evaluate trial conduct and compliance with the protocol, SOPs, GCP, and applicable regulations

• A sponsor’s audit is independent and separate from routine monitoring or quality control functions

• Should be done by individuals who are independent of the clinical trials/systems-regular Monitor can’t do them.

Page 11: Common Mistakes  & Audits

FDA Audits

• Purpose: To ensure compliance

Type of Audits• Study-directed audits• Investigator-directed audits• For cause audits• Not for cause audits-routine surveillance

Page 12: Common Mistakes  & Audits

What FDA Looks For

• Who did what• Degree of delegation• Where study was performed• How/ where data were recorded• Drug accountability• Monitor contact & follow-up letters• Data audit

FIRST binder they ask for may be correspondence!

Page 13: Common Mistakes  & Audits

Recent FDA Findings

• Inclusion of individuals that did not meet the inclusion criteria.

• Continuing of individuals that should have been removed from the study.

• Study procedure errors (not following the study roadmap)

• Errors in dosing• Communication errors

Page 14: Common Mistakes  & Audits

What if the FDA shows up?• Do NOT panic!• Ask for their ID and Form 482• Give them ONLY what they specifically ask for• Try never to leave them alone• Put them in a room that has no other study materials• Be honest and helpful• Notify the Human Research Protection Office (HRPO)

at TTUHSC-In advance if possible• Notify the study sponsor-in advance if possible

Page 15: Common Mistakes  & Audits

FDA Audits

• FDA 482-Notice of Inspection (they’re coming)• FDA 483-Audit findings (BAD! Issued if they note

some kind of problem, you may or may not get a warning (action) letter with it)

• Establishment Inspection Report (EIR). This is an overall report of their visit-you’ll always get this.

• Action Letters: NAI-No Action IndicatedVAI-Voluntary action indicatedOAI-Other action indicated

Page 16: Common Mistakes  & Audits

The Corrective Action Plan

• PI MUST take responsibility– Do not play the Pass the Blame Game!

• Address each issue directly • Enlist the help of your sponsor and local

compliance team

Page 17: Common Mistakes  & Audits

FDA Regulatory Sanctions

• Formal disqualification• Clinical hold• Voluntary restrictions• Criminal prosecution

Page 18: Common Mistakes  & Audits

Long-term consequences

• Audit results are publicly accessible on the FDA website

• Only bad conduct makes the news-front page• Most pre-study questionnaires from sponsors ask if

you’ve ever been audited, received a 483. If you have they want a copy.

• Effects your reputation in the clinical research arena– Your commitment & ethics may be questioned

Page 19: Common Mistakes  & Audits

Points to Remember

• Audit Findings/Common Mistakes – The Informed Consent is most commonly cited in research litigation

• The PI is always responsible for all study activity and for all personnel performance

• Keep the IRB informed of all study changes and updates

Page 20: Common Mistakes  & Audits

QUESTIONS?